Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES-23)

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Immunoconjugate therapy for solid tumors faces challenges due to the physical barrier posed by tumor blood vessel endothelial cells.
• Previous work demonstrated that TES-23, an antibody targeting tumor endothelial cells, conjugated with neocarzinostatin (NCS), showed anti-tumor effects against KMT-17 fibrosarcoma.

Purpose of the Study:

• To investigate the efficacy of the TES-23-NCS immunoconjugate for targeting various solid tumors.
• To evaluate the anti-tumor effects and tumor accumulation of TES-23 in different tumor models.

Main Methods:

• Conjugation of TES-23 monoclonal antibody with neocarzinostatin (NCS).
• Administration of (125)I-labeled TES-23 to mice bearing Meth-A fibrosarcoma and Colon 26 adenocarcinoma.
• Assessment of tumor accumulation of TES-23 compared to control IgG.
• Evaluation of anti-tumor effects and survival rates in mice treated with the immunoconjugate.

Main Results:

• TES-23 demonstrated greater accumulation in Meth-A fibrosarcoma and Colon 26 adenocarcinoma tumors compared to control IgG.
• Treatment with the TES-23-NCS immunoconjugate resulted in improved survival rates in mice bearing Meth-A fibrosarcoma.
• No observable side effects were reported in the treated mice.

Conclusions:

• The TES-23 immunoconjugate shows promise for targeting tumor vasculature across different solid tumor types.
• The findings suggest the presence of common antigens on various tumor endothelial cells recognized by TES-23.
• This approach offers a potential strategy for effective cancer therapy with minimal toxicity.